ATHE Stock Summary and Trading Ideas (Alterity Therapeutics Limited - American Depositary Shares | NASDAQ:ATHE)

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

Alterity Therapeutics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ATHE.

As of December 5, 2025, ATHE stock price declined to $3.42 with 8,718 million shares trading.

ATHE has a beta of 1.26, meaning it tends to be more sensitive to market movements. ATHE has a correlation of 0.03 to the broad based SPY ETF.

ATHE has a market cap of $61.99 million. This is considered a Micro Cap stock.

In the last 3 years, ATHE traded as high as $7.00 and as low as $1.00.

ATHE has outperformed the market in the last year with a return of +76.3%, while the SPY ETF gained +14.2%. However, in the most recent history, ATHE shares have underperformed the stock market with its stock returning -32.5% in the last 3 month period and -2.6% for the last 2 week period, while SPY has returned +6.2% and +4.0%, respectively.

ATHE support price is $3.24 and resistance is $3.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATHE shares will trade within this expected range on the day.